Compare Eli Lilly And Co (LLY) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Lamb Weston Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,221.61 (market cap $1.08T), while Lamb Weston Holdings Inc trades at $53.12 (market cap $7.23B). The key difference: Eli Lilly And Co is far larger — about 149.4× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| LLY | LW | |
|---|---|---|
Market Cap | $1.08T | $7.23B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $66.57 |
52-Week Low | $639.43 | $38.48 |
Enterprise Value | $1.13T | $11.10B |
Dividend Yield | 0.57% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Lamb Weston (LW) trades at $53.04, up 2.37% today, near its consensus price target of $53.86. The stock shows a bullish technical trend with consistent earnings beats in recent quarters, including Q2 2026 EPS of $0.87 versus $0.626 expected. Revenue reached $6.45 billion in 2025, though net income margin declined to 4.39%. Analyst sentiment is mixed with 31.58% buy ratings, while institutional investors like Dimensional Fund Advisors increased holdings by 28.1% in Q1 2026 (SEC filing, 2026-07-29).
The outlook is cautiously optimistic given operational improvements and cost savings, but risks include international demand pressures and elevated costs. The stock offers a 3.1% dividend yield, with fiscal 2027 guidance projecting 1%-2% sales growth. Further upside depends on sustaining North American volume growth and margin stabilization amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
